Indication of GX-G3 is the chemotherapy induced neutropenia. GX-G3 is a long-acting G-CSF to be administered once per chemotherapy cycle. This candidate best-in-class drug was developed as an hybrid protein on the hybrid-Fc (hyFc) platform proprietary to Genexine, Inc.
hyFc technology is designed to have extended half life and eliminate antibody-mediated (ADCC) or complementary dependent (CDC) cytotoxicity responses.
Structure of hyFc fused G-CSF
Development status of G-CSF hyFc